Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis

Table 3 Estimated odds of serious infection for selected^a treatment strategies compared to anti-tumor necrosis factor biologics

Treatment strategy	Comparator	Odds ratio	Standard error	95% Confidence interval
Adalimumab	Infliximab	0.57	0.57	0.18	1.74
Certolizumab pegol	Infliximab	1.74	0.67	0.47	6.53
Natalizumab	Infliximab	0.58	0.60	0.18	1.88
Ustekinumab	Infliximab	0.30	0.66	0.08	1.08
Vedolizumab	Infliximab	0.55	0.58	0.18	1.74
Golimumab	Infliximab	1.26	0.80	0.26	6.05
Infliximab + azathioprine/6MP	Infliximab	0.81	0.50	0.30	2.17
Infliximab + azathioprine/6MP + prednisone	Infliximab	0.23	2.29	0.00	20.82
Certolizumab pegol	Adalimumab	3.08	0.62	0.91	10.37
Natalizumab	Adalimumab	1.03	0.54	0.36	2.94
Ustekinumab	Adalimumab	0.52	0.60	0.16	1.71
Vedolizumab	Adalimumab	0.98	0.52	0.35	2.71
Golimumab	Adalimumab	2.22	0.76	0.50	9.78
Natalizumab	Certolizumab pegol	0.34	0.64	0.10	1.18
Ustekinumab	Certolizumab pegol	0.17	0.70	0.04	0.67
Vedolizumab	Certolizumab pegol	0.32	0.63	0.09	1.09
Golimumab	Certolizumab pegol	0.72	0.84	0.14	3.71

ISSN: 1471-230X